Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7312-7323

  Coen, Natacha ^a   Duraffour, Sophie ^a   Topalis, Dimitri ^a   Snoeck, Robert ^a   Andrei, Graciela ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ACYCLIC NUCLEOSIDE; CYTIDINE DERIVATIVE; FOSCARNET; GANCICLOVIR; NUCLEOSIDE DERIVATIVE; PENCICLOVIR; PURINE NUCLEOSIDE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; PYROPHOSPHORIC ACID DERIVATIVE; THYMIDINE KINASE; URIDINE DERIVATIVE; ANTIVIRUS AGENT; BROXURIDINE; CYTARABINE; DNA DIRECTED DNA POLYMERASE; FIACITABINE; PROTEIN KINASE; SORIVUDINE; URACIL ARABINOSIDE; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CROSS RESISTANCE; DRUG STRUCTURE; EPSTEIN BARR VIRUS; GAMMAHERPESVIRINAE; HUMAN HERPESVIRUS 8; IN VITRO STUDY; RHADINOVIRUS; SEQUENCE ANALYSIS; STRUCTURE ACTIVITY RELATION; VIRUS RESISTANCE; VIRUS STRAIN; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANIMAL; ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; SEQUENCE ALIGNMENT;

ACYCLOVIR; AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BROMODEOXYURIDINE; CYTARABINE; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FOSCARNET; GANCICLOVIR; HERPESVIRUS 4, HUMAN; HERPESVIRUS 8, HUMAN; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN KINASES; RHADINOVIRUS; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE KINASE; VIRAL PROTEINS;

EID: 84912142106     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03957-14     Document Type: Article

References (51)

1. Ambinder R, Cesarmen E. 2007. Clinical and pathological aspectes of EBV and KSHV infection, p 885-903. In Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
2. Ackermann M. 2006. Pathogenesis of gammaherpesvirus infections. Vet. Microbiol. 113:211-222. http://dx.doi.org/10.1016/j.vetmic.2005.11.008.
3. Blossom D. 2007. EBV and KSHV-related herpesviruses in non-human primates, p 1093-1114. In Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K (ed), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
4. Andrei G, De Clercq E, Snoeck R. 2009. Viral DNA polymerase inhibitors. In Cameron CE, Matthias G, Kevin R (ed), Viral genome replication. Springer, New York, NY.
5. Friedrichs C, Neyts J, Gaspar G, De Clercq E, Wutzler P. 2004. Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Ep-stein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res. 62:121-123. http://dx.doi.org/10.1016/j.antiviral.2003.12.005.
6. Medveczky MM, Horvath E, Lund T, Medveczky PG. 1997. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS 11:1327-1332. http://dx.doi.org/10.1097/00002030-199711000 -00006.
7. Meerbach A, Holy A, Wutzler P, De Clercq E, Neyts J. 1998. Inhibitory effects of novel nucleoside and nucleotide analogues on Epstein-Barr virus replication. Antivir. Chem. Chemother. 9:275-282.
8. Neyts J, De Clercq E. 1997. Antiviral drug susceptibility of human herpesvirus8 Antimicrob. Agents Chemother. 41:2754-2756
9. Bacon TH, Boyd MR. 1995. Activity of penciclovir against Epstein-Barr virus. Antimicrob. Agents Chemother. 39:1599-1602.
10. Lin JC, De Clercq E, Pagano JS. 1987. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob. Agents Chemother. 31:1431-1433.
11. Lin JC, Machida H. 1988. Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2=-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication. Antimicrob. Agents Chemother. 32:1068-1072.
12. Meerbach A, Klocking R, Meier C, Lomp A, Helbig B, Wutzler P. 2000. Inhibitory effect of cyclosaligenyl-nucleoside monophosphates (cycloSal-NMP) of acyclic nucleoside analogues on HSV-1 and EBV. Antiviral Res. 45:69-77. http://dx.doi.org/10.1016/S0166-3542(99)00076-5.
13. Sergerie Y, Boivin G. 2003. Evaluation of susceptibility of human herpesvirus 8 to antiviral drugs by quantitative real-time PCR. J. Clin. Microbiol. 41:3897-3900. http://dx.doi.org/10.1128/JCM.41.8.3897-3900.2003.
14. Neyts J, De Clercq E. 1998. In vitro and in vivo inhibition of murine gamma herpesvirus 68 replication by selected antiviral agents. Antimicrob. Agents Chemother. 42:170-172.
15. De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J. 2001. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev. Med. Virol. 11:381-395. http://dx.doi.org/10.1002/rmv.336.
16. Neyts J, Naesens L, Ying C, De Bolle L, De Clercq E. 2001. Antiherpesvirus activity of (1 = S,2 = R)-9-[[1 =, 2 = -bis(hydroxymethyl)-cycloprop-1=-yl]methyl] guanine (A-5021) in vitro and in vivo. Antiviral Res. 49:115-120. http://dx.doi.org/10.1016/S0166-3542(00)00144-3.
17. Gustafson EA, Chillemi AC, Sage DR, Fingeroth JD. 1998. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob. Agents Chemother. 42:2923-2931.
18. Gustafson EA, Schinazi RF, Fingeroth JD. 2000. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J. Virol. 74:684-692. http://dx.doi.org/10.1128/JVI.74.2.684 -692.2000.
19. Lock MJ, Thorley N, Teo J, Emery VC. 2002. Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J. Antimicrob. Chemother. 49:359-366. http: //dx.doi.org/10.1093/jac/49.2.359.
20. Cannon JS, Hamzeh F, Moore S, Nicholas J, Ambinder RF. 1999. Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J. Virol. 73:4786-4793.
21. Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC. 2010. The Epstein-Barr virus (EBV)-encoded protein kinase, EBVPK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J. Virol. 84:4534-4542. http://dx.doi.org/10.1128/JVI.02487-09.
22. Littler E, Arrand JR. 1988. Characterization of the Epstein-Barr virusencoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems. J. Virol. 62:3892-3895.
23. Gershburg E, Pagano JS. 2008. Conserved herpesvirus protein kinases. Biochim. Biophys. Acta 1784:203-212. http://dx.doi.org/10.1016/j.bbapap .2007.08.009.
24. Whitehurst CB, Sanders MK, Law M, Wang FZ, Xiong J, Dittmer DP, Pagano JS. 2013. Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase. J. Virol. 87:5311-5315. http://dx.doi.org /10.1128/JVI.03505-12.
25. Gershburg E, Hong K, Pagano JS. 2004. Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication. Antimicrob. Agents Chemother. 48:1900-1903. http: //dx.doi.org/10.1128/AAC.48.5.1900-1903.2004.
26. Wang FZ, Roy D, Gershburg E, Whitehurst CB, Dittmer DP, Pagano JS. 2009. Maribavir inhibits Epstein-Barr virus transcription in addition to viral DNA replication. J. Virol. 83:12108-12117. http://dx.doi.org/10 .1128/JVI.01575-09.
27. Gilbert C, Bestman-Smith J, Boivin G. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Updat. 5:88-114. http://dx.doi.org/10.1016/S1368-7646(02)00021-3.
28. Sasadeusz JJ, Tufaro F, Safrin S, Schubert K, Hubinette MM, Cheung PK, Sacks SL. 1997. Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. J. Virol. 71:3872-3878.
29. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712. http://dx.doi.org/10.1128 /CMR.00009-10.
30. Chou S. 2008. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev. Med. Virol. 18:233-246. http://dx.doi.org/10.1002 /rmv.574.
31. Romain CA, BHJ, Vezina HE, Holman CJ. 2010. A method for evaluating antiviral drug susceptibility of Epstein-Barr virus. Virus Adapt. Treat. 2010:1-7. http://dx.doi.org/10.2147/VAAT.S8575.
32. Wu CC, Chen MC, Chang YR, Hsu TY, Chen JY. 2004. Identification and characterization of the conserved nucleoside-binding sites in the Ep-stein-Barr virus thymidine kinase. Biochem. J. 379:795-803. http://dx.doi .org/10.1042/BJ20031832.
33. Wu CC, Hsu TY, Chen JY. 2005. Characterization of three essential residues in the conserved ATP-binding region of Epstein-Barr virus thymidine kinase. Biochemistry 44:4785-4793. http://dx.doi.org/10.1021 /bi0484872.
34. Gill MB, Murphy JE, Fingeroth JD. 2005. Functional divergence of Kaposi's sarcoma-associated herpesvirus and related gamma-2 herpesvirus thymidine kinases: novel cytoplasmic phosphoproteins that alter cellular morphology and disrupt adhesion. J. Virol. 79:14647-14659. http: //dx.doi.org/10.1128/JVI.79.23.14647-14659.2005.
35. Coen N, Singh U, Vuyyuru V, Van den Oord JJ, Balzarini J, Duraffour S, Snoeck R, Cheng YC, Chu CK, Andrei G. 2013. Activity and mechanism of action of HDVD, a novel pyrimidine nucleoside derivative with high levels of selectivity and potency against gammaherpesviruses. J. Virol. 87:3839-3851. http://dx.doi.org/10.1128/JVI.03338-12.
36. Andrei G, Snoeck R, Reymen D, Liesnard C, Goubau P, Desmyter J, De Clercq E. 1995. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur. J. Clin. Microbiol. Infect. Dis. 14:318-329.
37. Andrei G, Snoeck R, Goubau P, Desmyter J, De Clercq E. 1992. Comparative activity of various compounds against clinical strains of herpes simplex virus. Eur. J. Clin. Microbiol. Infect. Dis. 11:143-151.
38. Coen N, Duraffour S, Haraguchi K, Balzarini J, van den Oord JJ, Snoeck R, Andrei G. 2014. Antiherpesvirus activities of two novel 4=-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases. Antimicrob. Agents Chemother. 58: 4328-4340. http://dx.doi.org/10.1128/AAC.02825-14.
39. Pepper SD, Stewart JP, Arrand JR, Mackett M. 1996. Murine gamma-herpesvirus-68 encodes homologues of thymidine kinase and glycoprotein H: sequence, expression, and characterization of pyrimidine kinase activity. Virology 219:475-479.
40. Lowe DM, Alderton WK, Ellis MR, Parmar V, Miller WH, Roberts GB, Fyfe JA, Gaillard R, Ertl P, Snowden W. 1995. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrob. Agents Chemother. 39:1802-1808.
41. Li F, Maag H, Alfredson T. 2008. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J. Pharm. Sci. 97:1109-1134. http://dx.doi.org/10.1002/jps.21047.
42. Andrei G, Snoeck R. 2013. Advances in the treatment of varicella-zoster virus infections. Adv. Pharmacol. 67:107-168. http://dx.doi.org/10.1016 /B978-0-12-405880-4.00004-4.
43. th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, San Francisco, CA.
44. Suzuki M, Okuda T, Shiraki K. 2006. Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 72:157-161. http://dx.doi.org/10 .1016/j.antiviral.2006.05.001.
45. Tung PP, Summers WC. 1994. Substrate specificity of Epstein-Barr virus thymidine kinase. Antimicrob. Agents Chemother. 38:2175-2179.
46. De Clercq E. 2005. (E)-5-(2-bromovinyl)-2= -deoxyuridine (BVDU). Med. Res. Rev. 25:1-20. http://dx.doi.org/10.1002/med.20011.
47. Straus SE. 2012. Unanticipated risks in clinical development, p 77-95. In Ognibene FP, Gallin JI (ed), Principles and practice of clinical research. Academic Press, Waltham, MA.
48. Hwang YT, Zuccola HJ, Lu Q, Hwang CB. 2004. A point mutation within conserved region VI of herpes simplex virus type 1 DNA polymerase confers altered drug sensitivity and enhances replication fidelity. J. Virol. 78:650-657. http://dx.doi.org/10.1128/JVI.78.2.650-657.2004.
49. Tian W, Hwang YT, Hwang CB. 2008. The enhanced DNA replication fidelity of a mutant herpes simplex virus type 1 DNA polymerase is mediated by an improved nucleotide selectivity and reduced mismatch extension ability. J. Virol. 82:8937-8941. http://dx.doi.org/10.1128/JVI.00911-08.
50. Bestman-Smith J, Boivin G. 2003. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J. Virol. 77:7820-7829. http://dx .doi.org/10.1128/JVI.77.14.7820-7829.2003.
51. Walling DM, Flaitz CM, Nichols CM. 2003. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. J. Infect. Dis. 188:883-890. http://dx.doi.org /10.1086/378072.